History Making Operation Gives Man Two Prosthetic Arms And Hands He Can Control

Baugh completes a task showcasing his control of the MPL.: Image Credit: Johns Hopkins University Applied Physics Laborator
A Colorado man made history at the Johns Hopkins University Applied Physics Laboratory (APL) this summer when he became the first bilateral shoulder-level amputee to wear and simultaneously control two of the Laboratory’s Modular Prosthetic Limbs. Most importantly, Les Baugh, who lost both arms in an electrical accident 40 years ago, was able to operate the system by simply thinking about moving his limbs, performing a variety of tasks during a short training period. Baugh was in town for two weeks in June as part of an APL-funded research effort to further assess the usability of the MPL, developed over the past decade as part of the Revolutionizing Prosthetics Program. Before putting the limb system through the paces, Baugh had to undergo a surgery at Johns Hopkins Hospital known as targeted muscle
reinnervation. “It’s a relatively new surgical procedure that reassigns nerves that once controlled the arm and the hand,” explained Johns Hopkins Trauma Surgeon Albert Chi, M.D. “By reassigning existing nerves, we can make it possible for people who have had upper-arm amputations to control their prosthetic devices by merely thinking about the action they want to perform.” After recovery, Baugh visited the Laboratory for training on the use of the MPLs. First, he worked with researchers on the pattern recognition system. “We use pattern recognition algorithms to identify individual muscles that are contracting, how well they communicate with each other, and their amplitude and frequency,” Chi explained. “We take that information and translate that into actual movements within a prosthetic.”
Baugh completes a task showcasing his control of the MPL. Image Credit: Johns Hopkins University Applied Physics Laboratory
Then Baugh was fitted for a custom socket for his torso and shoulders that supports the prosthetic limbs and also makes the neurological connections with the reinnervated nerves. While the socket got its finishing touches, the team had him work with the limb system through a Virtual Integration Environment (VIE), a virtual-reality version of the MPL. The VIE is completely interchangeable with the prosthetic limbs and through APL’s licensing process currently provides 19 groups in the research community with a low-cost means of testing brain–computer interfaces. It’s being used to test novel neural interface methods and study phantom limb pain, and serves as a portable training system. By the time the socket
Bobby Armiger observes Baugh handing Albert Chi, M.D., a ball., Image Credit: Johns Hopkins University Applied Physics Laboratory
was finished, Baugh said he was more than ready to get started. When he was fitted with the socket, and the prosthetic limbs were attached, he said “I just went into a whole different world.” He moved several objects, including an empty cup from a counter-shelf height to a higher shelf, a task that required him to coordinate the control of eight separate motions to complete. “This task simulated activities that may commonly be faced in a day-to-day environment at home,” said APL’s Courtney Moran, a prosthetist working with Baugh. “This was significant because this is not possible with currently available prostheses. He was able to do this with only 10 days of training, which demonstrates the intuitive nature
APL prosthetist Courtney Moran looks on as Les Baugh tests out the Modular Prosthetic Limbs. , Image Credit: Johns Hopkins University Applied Physics Laboratory
of the control.” Moran said the research team was floored by what Baugh was able to accomplish. “We expected him to exceed performance compared to what he might achieve with conventional systems, but the speed with which he learned motions and the number of motions he was able to control in such a short period of time was far beyond expectation,” she said. “What really was amazing, and was another major milestone with MPL control, was his ability to control a combination of motions across both arms at the same time. This was a first for simultaneous bimanual control.” RP Principal Investigator Michael McLoughlin said “I think we are just getting started. It’s like the early days of the Internet. There is just a tremendous amount of potential ahead of us, and we’ve just started down this road. And I think the next five to 10 years are going to bring phenomenal advancement.” The next step, McLoughlin said, is to send Baugh home with a pair of limb systems so that he can see how they integrate with his everyday life. Baugh is looking forward to that day. “Maybe for once I’ll be able to put change in the pop machine and get pop out of it,” he said. He’s looking forward to doing “simple things that most people don’t think of. And it’s re-available to me.”  Contacts and sources:  Paulette Campbell, The Applied Physics Laboratory, The Johns Hopkins University,, Source: Article
Read More........

University of Delaware professor wins top bio-innovation prize

Aditja Kunjapur PHOTO: AAAS.org

Biomolecular engineer Aditya Kunjapur, assistant professor at the University of Delaware, Newark, Delaware, recently won the 2024 BioInnovation Institute & Science Prize for Innovation,

Kunjapur and his colleagues have found a way to create bacteria that build and incorporate a key amino acid into their own proteins, making it easier to fight infections.

For this work toward building a better platform for possible ifuture bacterial vaccines, Kunjapur is the winner of the 2024 BioInnovation Institute & SciencePrize for Innovation, the American Association for the Advancement of Science announced April 5, in a news item on aaas.org.

“The prize seeks to reward scientists who deliver research at the intersection of the life sciences and entrepreneurship,” it noted.

“Dr. Kunjapur’s outstanding research demonstrates the potential to engineer live bacterial cells to produce and incorporate nitrated amino acids into antigenic proteins, thus shining a spotlight on these proteins for the human immune system,” Michael Funk, senior editor at Science is quoted saying in the new release. “This work provides a platform for antigen engineering that is adaptable, specific, and amenable to safety controls.”

Vaccines against bacterial infections would likely decrease the need for antibiotic medicines, which in turn could stem the development of antibiotic resistance in some key drugs, AAAS noted.

Kunjapur estimates that bacterial vaccines will have an estimated global market size of $39.6 billion by 2030.

In his winning essay published April 5 in Science, Kunjapur writes — “our primary hypothesis is that engineering cells to access a broader chemical repertoire of building blocks can improve live bacterial vaccine efficacy.”

According to the news report, Kunjapur saw potential in a building block from earlier research in which a bacterial protein was modified with a non-standard amino acid called para-nitro-L-phenylalanine (nitro-Phe). The combination “triggered sustained production of antibodies in mice, suggesting that the altered amino acid was making it easier for the immune system to access or recognize the bacterial protein,” the news report noted.

Kunjapur and colleagues programmed E. coli bacterial cells to produce their own nitro-Phe and incorporate it into target proteins. The altered proteins hold the potential of becoming the basis for a live bacterial vaccine, the researchers suggest.

“In principle, the nitro-Phe modified protein produced by the engineered bacteria within a patient would lead to a targeted, sustained, and protective immune response towards bacterial pathogens,” even versions of the protein that haven’t been nitrated, Kunjapur is quoted saying.

Kunjapur also indicated that his team’s bioengineering strategy could work with other bacteria as well, not just E coli.

“We could also continue to use E. coli as a platform vector that makes recombinant proteins that belong to other bacteria,” he said. “So you can pick your chassis or your protein delivery vehicle, but the proteins you choose to nitrate should determine what immune cells respond to.”

Kunjapur hopes to work toward a vaccine for staph infections. The Covid pandemic came in the way of procuring funding for expanding his work, so Kunjapur used his own funds for the patent application.

“At the time I had cautious optimism in investing in new potential vaccine modalities during the height of a pandemic, but a lot of it was also a bet on the people behind the idea and our collaborators,” he said.

Kunjapur co-founded Nitro Biosciences, Inc. with his postdoc, Neil Butler, to pursue the nitro-Phe technology. He said starting the company has made him think more about who is going to use the technology, and what kind of criteria and metrics they need to know so that it can be used successfully.

The BioInnovation Institute & Science Prize for Innovation, the editors of Science “seek to recognize bold researchers who are asking fundamental questions at the intersection of the life sciences and entrepreneurship. We seek scientists who can show that they have reached across field boundaries with an enthusiasm that combines outstanding basic science with an eye toward application in the marketplace,” Science.org says on its website.

Located in Copenhagen, Denmark, the BioInnovation Institute foundation (BII) is an international commercial foundation with a nonprofit objective supported by the Novo Nordisk Foundation. “BII operates an incubator to accelerate world-class life science innovation that drives the development of new solutions by early life science start-ups for the benefit of people and society,” the Science.org website said. University of Delaware professor wins top bio-innovation prize
Read More........

Moderna CEO says melanoma vaccine could be available by 2025


WASHINGTON - Moderna CEO Stephane Bancel told AFP his company's experimental vaccine against melanoma could be available in as little as two years, in what would amount to a landmark step against the most serious form of skin cancer.

Globally there were an estimated 325,000 new melanoma cases and 57 ,000 deaths from the disease in 2020.

"We think that in some countries the product could be launched under accelerated approval by 2025," he said in an interview.


Unlike conventional vaccines, so-called therapeutic vaccines treat rather than prevent a disease. But they also work by training the body's own immune system against the invader.

Therapeutic vaccines today represent a real hope in oncology, an "immunotherapy 2.0," according to Bancel.

Moderna's aspirations received a boost Thursday with the latest clinical trial results showing an improvement over time in the chances of survival thanks to the vaccine, which uses the same messenger RNA technology that proved highly effective against serious forms of Covid-19.

In a study involving 157 people with advanced melanoma, the Moderna vaccine in combination with Merck's immunotherapy drug Keytruda reduced the risk of recurrence or death by 49 percent over a period of three years, compared with Keytruda alone.

Moderna had already announced two-year monitoring results last year, which showed a risk reduction of 44 percent.

"The difference in survival is growing. The more time passes, the more you see that advantage" said Bancel, noting that the rate of side effects hadn't increased.

"We have one in two people, compared to the best product on the market, who survive," he said, "which in oncology is huge."

- Seeking early approval -

The existing clinical evidence could thus form the basis for conditional approval of the vaccine, for now known as mRNA-4157, said Bancel.

Under this scenario, a larger, "phase three" study involving a thousand people that Moderna is carrying out in 2024 could confirm the earlier conditional authorization.

Both the US Food and Drug Administration and the European Medicines Agency have placed the therapy on an expedited review pathway.

The vaccine's development begins with sequencing the genome of each patient's tumor and identifying specific mutations to encode against. It is thus an example of "individualized" medicine tailored "just for you," said Bancel.

To prepare for market launch, Moderna is building a new factory in Massachusetts in order to have plentiful supply, a requirement of the FDA.

It also announced Monday that it was starting a phase 3 trial for an mRNA vaccine against lung cancer. Other types of tumors are also being studied.

Bancel's hope is to eventually pair these cancer vaccines with "liquid biopsies" -- groundbreaking tests that detect signs of tumors earlier, via blood tests, and are starting to become available in the United States.

The faster you can detect cancer, the better Moderna's new drugs will work, Bancel believes.

Other companies, such as BioNTech, are also working on individualized therapeutic cancer vaccines.

Read More........